Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 20 Publications

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504

Mol Cancer, 2014, 15:30

PubMed: 24927996

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801
Exp Gerontol, 2014, 52:55-69

PubMed: 24486130

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed:

Oncotarget, 2015, 51: S659-S660

PubMed:

Julius Maximilians Universit, 2014, Kumari G

PubMed:

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435

9 Customer Reviews

(A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

(A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.
SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.
Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.
UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.
Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\xUZk5UUN3ME2wMlAxODNyMzFOwG0>	M2rqXnNCVkeHUh?=
IST-MEL1	NWDhbJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLtTWM2OD1yLkCwNFQxPyEQvF2=	M4jLcHNCVkeHUh?=
NCI-SNU-1	NIi0XpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7xRmlQUUN3ME2wMlAxOjB5IN88US=>	M2e2NXNCVkeHUh?=
FADU	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITlOpJKSzVyPUCuNFAzODlizszN	MXnTRW5ITVJ?
C32	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWX0cYJ4UUN3ME2wMlAxOzB2IN88US=>	MXjTRW5ITVJ?
D-566MG	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHHd5pqUUN3ME2wMlAxOzlizszN	MonzV2FPT0WU
LXF-289	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkG2TWM2OD1yLkCwOFE6KM7:TR?=	MX\TRW5ITVJ?
HGC-27	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDF[Ik6UUN3ME2wMlAxPTFizszN	MmLGV2FPT0WU
RPMI-7951	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYX3RmtpUUN3ME2wMlAxPzF5IN88US=>	NVnY[IFJW0GQR1XS
HSC-3	NHjEW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TPSGlEPTB;MD6wNFkzQSEQvF2=	MlPVV2FPT0WU
MIA-PaCa-2	M3;mXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLHTWM2OD1yLkCxNFA6KM7:TR?=	NGX5SVhUSU6JRWK=
KS-1	NWjhZ2dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnW0TWM2OD1yLkCxN\|U2KM7:TR?=	MnPEV2FPT0WU
CAL-51	M3rhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEG2dotKSzVyPUCuNFE1ODVizszN	MU\TRW5ITVJ?
MDA-MB-361	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEG0PVUh\|ryP	NX;6bItbW0GQR1XS
TI-73	NIDIZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHiPJJnUUN3ME2wMlAyPzl4IN88US=>	M3WzSHNCVkeHUh?=
AGS	NWqwWZR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzpTWM2OD1yLkCxPVM5KM7:TR?=	Ml7GV2FPT0WU
NCI-H460	NES5TW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{K4[WlEPTB;MD6wNVk4PCEQvF2=	MnjRV2FPT0WU
A204	M1LadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwMEKyOFkh\|ryP	NFfPeHZUSU6JRWK=
CHL-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXPWXBKSzVyPUCuNFIzPTFizszN	NYe2T2Z3W0GQR1XS
DU-4475	M4\Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7wfpdKSzVyPUCuNFIzPjFizszN	NVfwOWtEW0GQR1XS
CGTH-W-1	MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEKzOFkh\|ryP	NHTnNHJUSU6JRWK=
HCC2218	NEW1fWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW1TWM2OD1yLkCyOFk1KM7:TR?=	MYXTRW5ITVJ?
A2780	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XBZ2lEPTB;MD6wNlU{OSEQvF2=	NVL6bnpGW0GQR1XS
NCI-H720	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\mTGlEPTB;MD6wNlU1PiEQvF2=	M3L0PXNCVkeHUh?=
NCI-N87	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLQTWM2OD1yLkCyOVk{KM7:TR?=	M2jBSHNCVkeHUh?=
CHP-212	NU[4R5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17Zd2lEPTB;MD6wNlYzQCEQvF2=	NGLGWYRUSU6JRWK=
NCI-H23	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\zbWlEPTB;MD6wNlY3PSEQvF2=	MYHTRW5ITVJ?
D-263MG	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnkZllKSzVyPUCuNFI4QDZizszN	NWnlNYdzW0GQR1XS
ME-180	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTzcpJSUUN3ME2wMlAzQDlzIN88US=>	Mmr3V2FPT0WU
SW982	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XXXGlEPTB;MD6wNlk6QSEQvF2=	NUfL[mU6W0GQR1XS
OE19	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vDeGlEPTB;MD6wN\|A4PyEQvF2=	MkC2V2FPT0WU
SK-LU-1	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnzRZJwUUN3ME2wMlA{ODh{IN88US=>	NH;jTmhUSU6JRWK=
H4	M1;jNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEOwPUDPxE1?	Ml36V2FPT0WU
HT-144	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\tTWM2OD1yLkCzNFk{KM7:TR?=	M3nzd3NCVkeHUh?=
SK-UT-1	NULnT\|NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7rSZRKSzVyPUCuNFMyPzhizszN	NIfUXGVUSU6JRWK=
D-336MG	NY\C[mRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7lNo1KSzVyPUCuNFM{ODlizszN	MUnTRW5ITVJ?
MDA-MB-175-VII	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH31OnpKSzVyPUCuNFM{PTRizszN	NGPsbHBUSU6JRWK=
GAMG	NYDXXIt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTBwMEO0N\|Uh\|ryP	NHu3WIZUSU6JRWK=
CP50-MEL-B	M4jK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMEO0OUDPxE1?	MW\TRW5ITVJ?
OVCAR-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml25TWM2OD1yLkCzOFgh\|ryP	NWC1NW1nW0GQR1XS
SK-MES-1	M1GzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7RWWZKUUN3ME2wMlA{PjB4IN88US=>	NIH4VGVUSU6JRWK=
VM-CUB-1	NFTD[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMEO2OVch\|ryP	NVTpOHRpW0GQR1XS
WM-115	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEO3OlIh\|ryP	NV:0VIZ6W0GQR1XS
DSH1	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEO4NFch\|ryP	MYXTRW5ITVJ?
Becker	NH;HcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvKTWM2OD1yLkCzPFg2KM7:TR?=	NY\U[2dqW0GQR1XS
SW962	NUPTPFAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zKRmlEPTB;MD6wN\|k1PSEQvF2=	M4\EeXNCVkeHUh?=
TYK-nu	M{[ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrsZ\|I2UUN3ME2wMlA{QTh3IN88US=>	MnvNV2FPT0WU
HO-1-N-1	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPKZmFPUUN3ME2wMlA1ODJzIN88US=>	M3z3WXNCVkeHUh?=
T98G	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\PfGlEPTB;MD6wOFExOyEQvF2=	MlTSV2FPT0WU
ACN	M37mTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fVdWlEPTB;MD6wOFE3OiEQvF2=	MVLTRW5ITVJ?
SW780	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrPTWM2OD1yLkC0NlA{KM7:TR?=	MUDTRW5ITVJ?
Detroit562	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrOTWM2OD1yLkC0NlM6KM7:TR?=	MWXTRW5ITVJ?
BB49-HNC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33yOWlEPTB;MD6wOFI1OyEQvF2=	Mmq5V2FPT0WU
HN	NWfGdJBzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3izfmlEPTB;MD6wOFI4OiEQvF2=	MlnlV2FPT0WU
H9	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfjS3l[UUN3ME2wMlA1OzdzIN88US=>	M3PXdXNCVkeHUh?=
VA-ES-BJ	NIHOOXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P2bWlEPTB;MD6wOFQ1PyEQvF2=	M2fLXHNCVkeHUh?=
MEL-JUSO	M3zRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULiTVhJUUN3ME2wMlA1PDd3IN88US=>	NGDk[FVUSU6JRWK=
BT-474	M2\kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3oTWM2OD1yLkC0OUDPxE1?	NHjPT3ZUSU6JRWK=
CaR-1	M13L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DRcWlEPTB;MD6wOFU1QSEQvF2=	NFe5c5RUSU6JRWK=
PSN1	NI\nSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInIb3NKSzVyPUCuNFQ3ODNizszN	NGrtV2xUSU6JRWK=
KYSE-510	NUjoZWNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\hZllKSzVyPUCuNFQ3PDlizszN	NVvsUoVtW0GQR1XS
KP-4	NWXSXXhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\rbm97UUN3ME2wMlA1PzV\|IN88US=>	NVzZOI9[W0GQR1XS
KYSE-410	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH6TWM2OD1yLkC0O\|czKM7:TR?=	M{nld3NCVkeHUh?=
G-402	NV3ScIJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfUTWM2OD1yLkC0O\|g6KM7:TR?=	M4[2VXNCVkeHUh?=
DOK	M37o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr4TWM2OD1yLkC0PVAzKM7:TR?=	NWPhZYptW0GQR1XS
COR-L88	NUHQXGtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwMES5NVIh\|ryP	NXH6b2hZW0GQR1XS
SKG-IIIa	NWLIXlI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMES5PFYh\|ryP	M{XDfHNCVkeHUh?=
AN3-CA	M17PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\0TWM2OD1yLkC1JO69VQ>?	NEeyNoVUSU6JRWK=
SW48	MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXqXVV5UUN3ME2wMlA2ODN7IN88US=>	MWnTRW5ITVJ?
YKG-1	MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEWwO\|Eh\|ryP	NW\rNmJNW0GQR1XS
KYSE-150	NYnGS2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvFPJNpUUN3ME2wMlA2OjN3IN88US=>	MoCyV2FPT0WU
HuO-3N1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\wVnhKSzVyPUCuNFUzOzdizszN	NGjFd2xUSU6JRWK=
LB1047-RCC	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjz[2NKSzVyPUCuNFUzQTZizszN	NWf5bIVHW0GQR1XS
NCI-H2030	NVm5TI9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMEW0NVQh\|ryP	M2jLUXNCVkeHUh?=
YH-13	NFP4[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{eyNmlEPTB;MD6wOVczOiEQvF2=	MXHTRW5ITVJ?
5637	MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEW3OEDPxE1?	NVzOepI3W0GQR1XS
LOXIMVI	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4THbmlEPTB;MD6wOVg4OiEQvF2=	M{jHTnNCVkeHUh?=
GT3TKB	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrGe5ZKSzVyPUCuNFU6PDJizszN	NXfNe\|FEW0GQR1XS
TCCSUP	NF3INIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXNd3ROUUN3ME2wMlA2QTZ2IN88US=>	Mo[5V2FPT0WU
EPLC-272H	NUPucYFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLNcGpXUUN3ME2wMlA3OjB3IN88US=>	NWexdmdEW0GQR1XS
LU-99A	NWCwfHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;rTmlEPTB;MD6wOlI{PyEQvF2=	MofFV2FPT0WU
NCI-H1755	NUTifmIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwME[zOFEh\|ryP	M3XwZ3NCVkeHUh?=
KM12	Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwME[zOFgh\|ryP	NIHxW3NUSU6JRWK=
SF295	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDGR2pMUUN3ME2wMlA3PDV{IN88US=>	MorlV2FPT0WU
MZ2-MEL	NIT0WXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwME[1OVMh\|ryP	NIHMeZlUSU6JRWK=
HEC-1	M2\ZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYO0bm9MUUN3ME2wMlA3PTh6IN88US=>	M1n6RnNCVkeHUh?=
SW684	M1HkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\pTWM2OD1yLkC2OVkyKM7:TR?=	M{nWfHNCVkeHUh?=
SF539	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnG4TWM2OD1yLkC2OlgyKM7:TR?=	MmXhV2FPT0WU
GMS-10	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jURmlEPTB;MD6wOlY6QSEQvF2=	M3TSSnNCVkeHUh?=
MV-4-11	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\tcXVlUUN3ME2wMlA3QDB\|IN88US=>	NGOwSFRUSU6JRWK=
HT-29	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fxRmlEPTB;MD6wOlkyQSEQvF2=	NWq1PGZQW0GQR1XS
23132-87	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S4R2lEPTB;MD6wOlk2KM7:TR?=	NFjY[INUSU6JRWK=
SW620	NHnV[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMEewNlYh\|ryP	NVHSWmNPW0GQR1XS
HCC1806	M{D2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPpUFg2UUN3ME2wMlA4OTNzIN88US=>	M3vQNnNCVkeHUh?=
Hs-578-T	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMEeyNFgh\|ryP	NV;XfIJCW0GQR1XS
A2058	M2rJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwMEeyNlgh\|ryP	NEj5[GRUSU6JRWK=
MEL-HO	M3j1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO0OVRKSzVyPUCuNFczPTVizszN	NXz1OIc3W0GQR1XS
HCC2998	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnSTWM2OD1yLkC3N\|Q4KM7:TR?=	M{XS[HNCVkeHUh?=
HuO9	NUT6Nm1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDteoNKSzVyPUCuNFc2QDlizszN	MkHpV2FPT0WU
CAL-39	NWi3RoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorjTWM2OD1yLkC3O\|Y3KM7:TR?=	MmPUV2FPT0WU
M14	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF23fHBKSzVyPUCuNFc6OTNizszN	MkC2V2FPT0WU
BFTC-909	NXf4eVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\rN4NGUUN3ME2wMlA4QTZ7IN88US=>	M{DmTXNCVkeHUh?=
TE-11	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXPTWM2OD1yLkC3PVk3KM7:TR?=	MYfTRW5ITVJ?
TGBC1TKB	M1HFemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjNdVVKSzVyPUCuNFgxPDNizszN	MWnTRW5ITVJ?
L-363	NH7QN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XKVmlEPTB;MD6wPFIxPiEQvF2=	MUDTRW5ITVJ?
A431	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3yxe2lEPTB;MD6wPFIyKM7:TR?=	Mle0V2FPT0WU
MKN45	NFzWdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzLO5hjUUN3ME2wMlA5OjF7IN88US=>	MofGV2FPT0WU
HT-1080	NFvReHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPxTWM2OD1yLkC4OFM6KM7:TR?=	MUXTRW5ITVJ?
OVCAR-8	NE\XV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\PWGZKSzVyPUCuNFg3OjJizszN	MlrLV2FPT0WU
LCLC-97TM1	NXLJUHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmyPJptUUN3ME2wMlA5PzJ6IN88US=>	M3H4V3NCVkeHUh?=
M059J	NHHvXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXKXWhzUUN3ME2wMlA6ODJ5IN88US=>	M2PyTXNCVkeHUh?=
SK-MEL-2	NVXQSY9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMEmwOkDPxE1?	M1r5Z3NCVkeHUh?=
TE-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jJbWlEPTB;MD6wPVIxPCEQvF2=	M1jHenNCVkeHUh?=
KYSE-180	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrZTWM2OD1yLkC5NlYzKM7:TR?=	MnfCV2FPT0WU
D-247MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\vc3pKSzVyPUCuNFk1PTVizszN	MVvTRW5ITVJ?
8-MG-BA	M17SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPs[WRCUUN3ME2wMlA6PDd{IN88US=>	NUDvZVFWW0GQR1XS
NCI-H1792	NH72V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PsNmlEPTB;MD6wPVYyQCEQvF2=	NUX0RYo1W0GQR1XS
MCF7	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL2R5U4UUN3ME2wMlA6Pjd5IN88US=>	NVrCWZlwW0GQR1XS
NCI-H2122	NHPRb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\yb2lEPTB;MD6wPVc1PSEQvF2=	M{L0VXNCVkeHUh?=
EFO-27	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LU[WlEPTB;MD6wPVk6PyEQvF2=	M{X2fnNCVkeHUh?=
LB2241-RCC	M3P3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTBwMUCwOVQh\|ryP	NHrpS3RUSU6JRWK=
SN12C	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMUCxNFch\|ryP	NX;DcWNFW0GQR1XS
A498	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\lTWM2OD1yLkGwNVgh\|ryP	NEP3[Y9USU6JRWK=
PANC-03-27	M4rJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMUCyPFYh\|ryP	NFjZUFBUSU6JRWK=
NCI-H1581	M1GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PpVWlEPTB;MD6xNFI6KM7:TR?=	MoLjV2FPT0WU
U-87-MG	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vYfGlEPTB;MD6xNFMxPyEQvF2=	MlTMV2FPT0WU
G-401	M13aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPCUldKSzVyPUCuNVA{PTNizszN	M1\WdHNCVkeHUh?=
SiHa	M1rueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4myW2lEPTB;MD6xNFQ5PiEQvF2=	NGrVUoJUSU6JRWK=
U251	NITYdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMUC1NlUh\|ryP	Mn3TV2FPT0WU
MMAC-SF	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS3SIlTUUN3ME2wMlExPTNzIN88US=>	NEnJUWJUSU6JRWK=
BB65-RCC	NIPze4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnNPWFKSzVyPUCuNVA2PTRizszN	NHL6ZpVUSU6JRWK=
NKM-1	M1vsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMUC2OlYh\|ryP	M2rSfXNCVkeHUh?=
HD-MY-Z	M2i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH74V\|ZKSzVyPUCuNVA5PzNizszN	NXHuWZZ3W0GQR1XS
TGBC11TKB	NGnzUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nJWGlEPTB;MD6xNFkxOyEQvF2=	MlrzV2FPT0WU
COLO-679	Mn;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMUGyNVEh\|ryP	MmPtV2FPT0WU
TE-8	M1zuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzDc4NXUUN3ME2wMlEyOjZ2IN88US=>	NEDTUoVUSU6JRWK=
SK-MEL-28	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFO5S41KSzVyPUCuNVE{OjFizszN	M2DLRXNCVkeHUh?=
SH-4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fP[WlEPTB;MD6xNVM2PiEQvF2=	NWfCXGN{W0GQR1XS
KALS-1	Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMUGzPVMh\|ryP	MV;TRW5ITVJ?
RKO	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTZNVNNUUN3ME2wMlEyPzZ2IN88US=>	NXvQbZplW0GQR1XS
OMC-1	M3u4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMUG3PVch\|ryP	Mm\ZV2FPT0WU
BT-549	NYq2[mFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnZTWM2OD1yLkGxO\|k6KM7:TR?=	MVTTRW5ITVJ?
NCI-H28	NYrYZYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\STWM2OD1yLkGxPFE4KM7:TR?=	MmHRV2FPT0WU
RXF393	M3TYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMUG5PFIh\|ryP	M4Xj[XNCVkeHUh?=
COLO-829	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMUKwNFUh\|ryP	NWrEfnB6W0GQR1XS
HMV-II	MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfETWM2OD1yLkGyNFIh\|ryP	MXvTRW5ITVJ?
SW1990	NGG2OIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMUKxOVch\|ryP	NGnmUINUSU6JRWK=
NCI-H1437	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnwTWM2OD1yLkGyNVU4KM7:TR?=	M1H2d3NCVkeHUh?=
SNB75	M3jWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwMUKxOlkh\|ryP	MXLTRW5ITVJ?
EW-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIr1dnhKSzVyPUCuNVI3PjFizszN	NEHpfoJUSU6JRWK=
SAS	NXvKTlhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\y[GlEPTB;MD6xNlY6KM7:TR?=	NVzVTmZ3W0GQR1XS
NCI-H1666	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PCUGlEPTB;MD6xNlc4PCEQvF2=	M4XEVHNCVkeHUh?=
A375	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;NfWlEPTB;MD6xNlc4QCEQvF2=	MXnTRW5ITVJ?
CAMA-1	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:xTWM2OD1yLkGyPVI1KM7:TR?=	MWHTRW5ITVJ?
HuP-T4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{freGlEPTB;MD6xNlk1OyEQvF2=	MWfTRW5ITVJ?
NCI-H292	M1vlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmKzTWM2OD1yLkGzNVEh\|ryP	NUGzWWZuW0GQR1XS
PC-14	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXBSoxKSzVyPUCuNVMzOTFizszN	NX7LNogxW0GQR1XS
BPH-1	NETOUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;aTWM2OD1yLkGzOFEh\|ryP	MoPNV2FPT0WU
GAK	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMUO1Olch\|ryP	Ml\zV2FPT0WU
VMRC-RCZ	NE\ZO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPPOIdHUUN3ME2wMlE{PzZ{IN88US=>	NH60e\|ZUSU6JRWK=
SK-MEL-24	M4eyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1u5T2lEPTB;MD6xN\|g4KM7:TR?=	M{LHc3NCVkeHUh?=
LB831-BLC	Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWToPItuUUN3ME2wMlE{QDh\|IN88US=>	M3rkS3NCVkeHUh?=
NCI-H2452	NFzNZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX36coRYUUN3ME2wMlE{QTV4IN88US=>	MVHTRW5ITVJ?
RT-112	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\LOYlKSzVyPUCuNVQxOzVizszN	Moq5V2FPT0WU
GP5d	NXrtOoFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYK5cYFzUUN3ME2wMlE1OTB2IN88US=>	M4G5PXNCVkeHUh?=
LC-2-ad	M2nYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW[5N21pUUN3ME2wMlE1OTJzIN88US=>	MoDmV2FPT0WU
MPP-89	M4LwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjlN3VpUUN3ME2wMlE1OTJ3IN88US=>	NFvKdI9USU6JRWK=
NUGC-3	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnre5VkUUN3ME2wMlE1PDd6IN88US=>	MYTTRW5ITVJ?
GI-1	M4[yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTiN2VKSzVyPUCuNVQ2PThizszN	MmjNV2FPT0WU
HCC1419	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTp[mJ{UUN3ME2wMlE1PTd4IN88US=>	MXTTRW5ITVJ?
SW1573	NGjxVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D3TGlEPTB;MD6xOFc2QCEQvF2=	NHTYOIZUSU6JRWK=
NCI-H2347	NGLTN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7oTWM2OD1yLkG0PFM6KM7:TR?=	MVfTRW5ITVJ?
Mewo	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF70cJFKSzVyPUCuNVQ5QDlizszN	MUDTRW5ITVJ?
639-V	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm4TWM2OD1yLkG1NFE{KM7:TR?=	M4HGOnNCVkeHUh?=
AsPC-1	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFewcIZKSzVyPUCuNVUzOjVizszN	NYHEN4toW0GQR1XS
NCI-H1648	MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnITWM2OD1yLkG1NlMzKM7:TR?=	NX\4VYo2W0GQR1XS
786-0	MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HkcWlEPTB;MD6xOVM5OSEQvF2=	M4nCNHNCVkeHUh?=
ETK-1	M2f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMUW5JO69VQ>?	MnvZV2FPT0WU
BxPC-3	M2fmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMUW5OlYh\|ryP	M4HqPHNCVkeHUh?=
CAL-62	Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXOd\|BKSzVyPUCuNVYyPjlizszN	M3jRNHNCVkeHUh?=
HCC1937	NHn6eVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;4bmhKSzVyPUCuNVYzPzVizszN	Ml7nV2FPT0WU
NCI-H1299	NYTYeoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M332UWlEPTB;MD6xOlI5PSEQvF2=	NH[zS3dUSU6JRWK=
SW1088	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMU[0NVMh\|ryP	NFfWbFNUSU6JRWK=
FTC-133	NGrkXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO5TolrUUN3ME2wMlE3PTRizszN	Mn;DV2FPT0WU
OC-314	M3TRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMU[2PUDPxE1?	M2j1e3NCVkeHUh?=
SCC-9	NX7leHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy5PWVtUUN3ME2wMlE3PzF4IN88US=>	MWPTRW5ITVJ?
HT-1376	NVzZZoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMU[5N\|Yh\|ryP	MlK3V2FPT0WU
U-2-OS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HaUWlEPTB;MD6xO\|E4OyEQvF2=	NH;0dGNUSU6JRWK=
COLO-824	NXzHSGJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2GwdGlEPTB;MD6xO\|I6PCEQvF2=	Mo\QV2FPT0WU
BB30-HNC	M3W0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmj3TWM2OD1yLkG3N\|Mh\|ryP	MU\TRW5ITVJ?
NCI-H2087	M3myfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGH6XXRKSzVyPUCuNVc{PjhizszN	MX\TRW5ITVJ?
NCI-H2170	NG[2cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTsTWM2OD1yLkG3OVM3KM7:TR?=	NV;oVYpOW0GQR1XS
SK-OV-3	NVrPSJdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DBRWlEPTB;MD6xO\|U4OSEQvF2=	NYrmOplDW0GQR1XS
MZ7-mel	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXDTWM2OD1yLkG3OlQ6KM7:TR?=	NVT1OlZCW0GQR1XS
NCI-H650	NH;sZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWz[oNDUUN3ME2wMlE4Pjh{IN88US=>	NGnRdIRUSU6JRWK=
KOSC-2	NH;KdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMUe3N\|Qh\|ryP	NVT0dZFPW0GQR1XS
SCC-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTVTWM2OD1yLkG3O\|c4KM7:TR?=	M1LzSHNCVkeHUh?=
MDA-MB-157	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMUiwPFIh\|ryP	MYjTRW5ITVJ?
KYSE-520	NH61S4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPCTWM2OD1yLkG4NkDPxE1?	MoDNV2FPT0WU
LK-2	M4jzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPZTWM2OD1yLkG4N\|A{KM7:TR?=	MXrTRW5ITVJ?
KNS-81-FD	M2DUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPMV3VJUUN3ME2wMlE5Ozl2IN88US=>	MkHTV2FPT0WU
IGROV-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzPemY4UUN3ME2wMlE5PDR\|IN88US=>	NWT6cWc3W0GQR1XS
DEL	NV\SRpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfMTWM2OD1yLkG4OFUh\|ryP	NWPrVWNPW0GQR1XS
NCI-H1395	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X5OGlEPTB;MD6xPFY5OiEQvF2=	NFPLRXJUSU6JRWK=
JEG-3	NV7XT2lRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPOSYVIUUN3ME2wMlE5PzB3IN88US=>	MmjNV2FPT0WU
BCPAP	NVHVNXA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGCyblBKSzVyPUCuNVg5PzJizszN	M3;BUXNCVkeHUh?=
CAL-27	M1vFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7DTWM2OD1yLkG5NFIzKM7:TR?=	NYXPdFY5W0GQR1XS
RD	M1zicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwMUmxNVMh\|ryP	NXu4bGZWW0GQR1XS
RVH-421	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\uTWM2OD1yLkG5NVE3KM7:TR?=	NFjkd3JUSU6JRWK=
Capan-2	M2\lT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMUmyOVYh\|ryP	MW\TRW5ITVJ?
COLO-680N	NXvWcHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXCTWM2OD1yLkG5N\|Y1KM7:TR?=	NFqyUmRUSU6JRWK=
NCI-H1650	NIfuempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrkTWM2OD1yLkKwNFU4KM7:TR?=	MYrTRW5ITVJ?
SBC-5	NVPoTIw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknDTWM2OD1yLkKwNVE5KM7:TR?=	MU\TRW5ITVJ?
U031	NHvvRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;GO\|lKSzVyPUCuNlA2PDdizszN	M{XJ[HNCVkeHUh?=
S-117	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3iyfmlEPTB;MD6yNFU3PCEQvF2=	MVzTRW5ITVJ?
DoTc2-4510	NYXRUJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3K0cmlEPTB;MD6yNFc3QSEQvF2=	M3HOO3NCVkeHUh?=
AM-38	MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMkC4OFgh\|ryP	NYjXO5JNW0GQR1XS
A172	M3;Qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMkGwNlIh\|ryP	MXHTRW5ITVJ?
HPAF-II	NH3wNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWD3WppuUUN3ME2wMlIyOjZ2IN88US=>	M2HNPHNCVkeHUh?=
769-P	NYK2TlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;o[WlEPTB;MD6yNVI5KM7:TR?=	NUn0SGlCW0GQR1XS
MFE-280	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzxeoRKSzVyPUCuNlEzQThizszN	MY\TRW5ITVJ?
TE-9	NIexTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\X[2lEPTB;MD6yNVc5PiEQvF2=	MYXTRW5ITVJ?
C2BBe1	NVPV[4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDlTWM2OD1yLkKyNVkh\|ryP	MnntV2FPT0WU
EoL-1-cell	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DleWlEPTB;MD6yNlIxOyEQvF2=	NUn6d4pYW0GQR1XS
G-361	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMkK2PFIh\|ryP	NEjk[FZUSU6JRWK=
KYSE-270	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\iUmVOUUN3ME2wMlI{ODh2IN88US=>	MVvTRW5ITVJ?
TK10	M2PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLCTWM2OD1yLkKzNVE4KM7:TR?=	M13BdnNCVkeHUh?=
ML-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMkOxNVkh\|ryP	Mn\zV2FPT0WU
MHH-ES-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPYSFhKSzVyPUCuNlM3QDFizszN	MVzTRW5ITVJ?
BHY	MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGraS5ZKSzVyPUCuNlM3QTFizszN	MYDTRW5ITVJ?
LS-513	M{PGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV63TY9pUUN3ME2wMlI{QTZzIN88US=>	MUDTRW5ITVJ?
COLO-678	NGe5R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMkSwOFQh\|ryP	M1;qVnNCVkeHUh?=
NCI-H747	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\ZfJZ2UUN3ME2wMlI1OTZ7IN88US=>	MW\TRW5ITVJ?
K5	M1XPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIH3dFBKSzVyPUCuNlQ{QCEQvF2=	NFnXcoNUSU6JRWK=
OS-RC-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\mbY9KSzVyPUCuNlQ2ODlizszN	MXPTRW5ITVJ?
KINGS-1	M4XCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMkS1Nlkh\|ryP	MV;TRW5ITVJ?
SCC-25	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV23OlhnUUN3ME2wMlI1PTZ\|IN88US=>	M{DZRnNCVkeHUh?=
CAPAN-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojwTWM2OD1yLkK0O\|g{KM7:TR?=	MmfPV2FPT0WU
ESS-1	M1fwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfiTWM2OD1yLkK0PFA2KM7:TR?=	NFPrdoNUSU6JRWK=
TE-6	NUPqdIpRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPNTWM2OD1yLkK1O\|Uh\|ryP	MYLTRW5ITVJ?
LB2518-MEL	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfYV3RKSzVyPUCuNlU4PzdizszN	MUjTRW5ITVJ?
COLO-800	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMkW4NVIh\|ryP	MVjTRW5ITVJ?
LU-134-A	NH7uVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjyU2lKSzVyPUCuNlYyOzZizszN	NX60OGNbW0GQR1XS
NCI-H1155	NWTveYJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PHRWlEPTB;MD6yOlE3OiEQvF2=	MWDTRW5ITVJ?
MFM-223	NELG[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjpRmRKSzVyPUCuNlY{PjNizszN	MVjTRW5ITVJ?
HTC-C3	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTBwMk[1NFYh\|ryP	MXXTRW5ITVJ?
HCT-116	M{jZdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlO0TWM2OD1yLkK2OVk6KM7:TR?=	MWLTRW5ITVJ?
Ca-Ski	M1LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMk[2O\|gh\|ryP	MnvjV2FPT0WU
SBC-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1i0S2lEPTB;MD6yOlc1OiEQvF2=	NVnrSJJWW0GQR1XS
NB69	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fKVWlEPTB;MD6yO\|A5PyEQvF2=	MoTuV2FPT0WU
J82	NEDEc\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[0bnVbUUN3ME2wMlI4OjZ3IN88US=>	NWHxSHlpW0GQR1XS
U-118-MG	NWrUeZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMke1O\|kh\|ryP	NFvRSGxUSU6JRWK=
NCI-H1355	M17nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHwTWM2OD1yLkK4NFc1KM7:TR?=	M{L2dnNCVkeHUh?=
NCI-H1048	Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;DfXpKSzVyPUCuNlg6PTZizszN	M{LhV3NCVkeHUh?=
SW954	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMkmyNlch\|ryP	NWWwfZBkW0GQR1XS
NMC-G1	NIfNRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PNcmlEPTB;MD6yPVI4PyEQvF2=	NV7JW45wW0GQR1XS
SW1710	NVTlRm5sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwMkm0PVQh\|ryP	MnXkV2FPT0WU
KY821	M{XzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMkm4O\|Ih\|ryP	NH;0[oRUSU6JRWK=
HCC38	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rJXmlEPTB;MD6zNFA4QCEQvF2=	NF;jUo9USU6JRWK=
NCI-SNU-5	M3\rUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n1ZmlEPTB;MD6zNFU1KM7:TR?=	NIC1fVZUSU6JRWK=
ES8	NEnOeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fkS2lEPTB;MD6zNFc5PCEQvF2=	NVTwOJB1W0GQR1XS
COLO-792	NVjUcIY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWm1enF4UUN3ME2wMlMyOjVzIN88US=>	NIDUNHFUSU6JRWK=
BFTC-905	NHHlSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwM{G1NlEh\|ryP	NXzvc\|RnW0GQR1XS
ChaGo-K-1	NH7pO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;mWoJKSzVyPUCuN\|E4OTVizszN	NHHwOGhUSU6JRWK=
Daoy	M{j3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvlV2ZFUUN3ME2wMlMyPzJ\|IN88US=>	M135fnNCVkeHUh?=
SJSA-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwM{G4OFch\|ryP	Mm\VV2FPT0WU
KNS-62	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;kUGlEPTB;MD6zNlA5QCEQvF2=	NUXpPIZkW0GQR1XS
CAKI-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\abYhKSzVyPUCuN\|IyOTFizszN	NV33bmNpW0GQR1XS
UACC-62	NGC5TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\TOlVKSzVyPUCuN\|IzOjdizszN	M13ETXNCVkeHUh?=
HuCCT1	NXW3VnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrYeIFKSzVyPUCuN\|IzQDNizszN	MUTTRW5ITVJ?
CTB-1	MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwM{K3OVMh\|ryP	M3PSfHNCVkeHUh?=
NTERA-S-cl-D1	NIrPRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{GyR2lEPTB;MD6zNlg{PiEQvF2=	NF3obo9USU6JRWK=
T-24	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\WXWlEPTB;MD6zN\|E2QSEQvF2=	MYHTRW5ITVJ?
KYSE-70	M3r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHSTWM2OD1yLkOzNlg{KM7:TR?=	M1z5[3NCVkeHUh?=
SW626	NF7ie49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwM{O1N\|Ih\|ryP	MnPkV2FPT0WU
LB996-RCC	NF7IcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Lz[GlEPTB;MD6zN\|YyQSEQvF2=	M4fTPHNCVkeHUh?=
DMS-273	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwM{O5NVYh\|ryP	NFzQWZBUSU6JRWK=
SW1783	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwM{O5PVch\|ryP	NY\3T5IxW0GQR1XS
KU812	NViwcWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2WzUmlEPTB;MD6zOFA{QCEQvF2=	NHPGWVNUSU6JRWK=
HSC-2	M4jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXje\|ZbUUN3ME2wMlM1ODV\|IN88US=>	Mn;kV2FPT0WU
A3-KAW	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWCzRWlsUUN3ME2wMlM1OTZ{IN88US=>	NV;lTWJKW0GQR1XS
COLO-684	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfaRYlKSzVyPUCuN\|Q2ODFizszN	M1zZW3NCVkeHUh?=
NCI-H2405	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jCOmlEPTB;MD6zOFY{OSEQvF2=	NYPJR3R4W0GQR1XS
NCI-H2228	M1LV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknETWM2OD1yLkO1N\|U4KM7:TR?=	NYjEdZBHW0GQR1XS
NB13	M{\0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[3XGlEPTB;MD6zOlgzQSEQvF2=	NH;NbW1USU6JRWK=
no-11	MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3T0W2lEPTB;MD6zOlk2KM7:TR?=	NGfW[GZUSU6JRWK=
DK-MG	M3XyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{exPFgh\|ryP	NH;TU2xUSU6JRWK=
NBsusSR	NUXZ[m5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M36z[mlEPTB;MD6zO\|I5PSEQvF2=	NHTjT49USU6JRWK=
KP-N-YS	NIXqUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwM{e0OlMh\|ryP	MlSzV2FPT0WU
CFPAC-1	NWHiT\|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP6XY82UUN3ME2wMlM4PTF6IN88US=>	M121cHNCVkeHUh?=
KARPAS-45	NXGxfIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTQTWM2OD1yLkO3PFYzKM7:TR?=	MlvOV2FPT0WU
NCI-H1793	NUfG[4NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVP0eJJDUUN3ME2wMlM5PTFizszN	NH\oe4xUSU6JRWK=
HCE-T	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;XSYZoUUN3ME2wMlM5PjB\|IN88US=>	NUXZblJJW0GQR1XS
NCI-H520	M2fs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW5[Y9KSzVyPUCuN\|g4ODNizszN	MkLDV2FPT0WU
HCC2157	NYPLeXBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CzTWlEPTB;MD6zPFc5OSEQvF2=	NVvLUFZuW0GQR1XS
EW-18	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vycmlEPTB;MD6zPFk1OSEQvF2=	NYO2O4R4W0GQR1XS
RO82-W-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwM{m2PVkh\|ryP	M2PjTXNCVkeHUh?=
HuP-T3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLRblh1UUN3ME2wMlQxOTR\|IN88US=>	Mn3yV2FPT0WU
PANC-10-05	NFrKS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTZZXF[UUN3ME2wMlQyOTdizszN	MWnTRW5ITVJ?
NCI-H1703	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3i4eGlEPTB;MD60NVQ1PiEQvF2=	MVPTRW5ITVJ?
TE-10	NF\Fb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\je2pKSzVyPUCuOFE1PDdizszN	NGDweY9USU6JRWK=
HOS	MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXPOZR2UUN3ME2wMlQyPjh{IN88US=>	M1rhUXNCVkeHUh?=
LN-405	NYL2UZE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\ubogyUUN3ME2wMlQyPjh5IN88US=>	MYHTRW5ITVJ?
A427	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfVeFFRUUN3ME2wMlQyQThzIN88US=>	MXfTRW5ITVJ?
CAL-12T	MlHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fCNWlEPTB;MD60Nlc5KM7:TR?=	NX:5NHdnW0GQR1XS
SW756	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfiTWM2OD1yLkS0NVg{KM7:TR?=	M{XIcHNCVkeHUh?=
YAPC	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\hTWM2OD1yLkS1NFgh\|ryP	M1nuRXNCVkeHUh?=
GOTO	NF;VO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPGc4FKSzVyPUCuOFUyPiEQvF2=	M1zkPHNCVkeHUh?=
C3A	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXO5PZBMUUN3ME2wMlQ2PDN5IN88US=>	M2j0W3NCVkeHUh?=
UM-UC-3	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LQUGlEPTB;MD60OVQ4KM7:TR?=	MYfTRW5ITVJ?
NCI-H1573	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TJc2lEPTB;MD60OVU3QSEQvF2=	MkLEV2FPT0WU
LS-411N	NYW1bYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn24TWM2OD1yLkS2OVI4KM7:TR?=	MVjTRW5ITVJ?
COR-L23	M2W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHIb4hzUUN3ME2wMlQ3PzZ2IN88US=>	M3LHUnNCVkeHUh?=
HCE-4	NV;BNWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnsOWtVUUN3ME2wMlQ4PDR4IN88US=>	MmjBV2FPT0WU
NCI-H2291	NVi1d5hHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwNEe4PVYh\|ryP	NInYWXdUSU6JRWK=
A101D	M1TXTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnm5TWM2OD1yLkS4NFU{KM7:TR?=	NV7nPWxEW0GQR1XS
HT-3	NXfUV5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4frZmlEPTB;MD60PFIyPyEQvF2=	NF3EO2JUSU6JRWK=
HOP-62	NILUOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT0TWM2OD1yLkS5PFY2KM7:TR?=	M{LYR3NCVkeHUh?=
PC-3	NVLze5hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3oZXUxUUN3ME2wMlUyPTB5IN88US=>	NXPMW5l1W0GQR1XS
CTV-1	NVvWN5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrNS5VKSzVyPUCuOVI3PjlizszN	MXrTRW5ITVJ?
PANC-08-13	M3\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK2TWM2OD1yLkWzNVc4KM7:TR?=	NFntPZpUSU6JRWK=
CAL-120	M4XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:4e5hKSzVyPUCuOVM{QTlizszN	M2j4SXNCVkeHUh?=
UMC-11	NXvmUYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rle2lEPTB;MD61OVI{PCEQvF2=	MYLTRW5ITVJ?
MSTO-211H	NXizUYNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwNUW3OlIh\|ryP	NEjHWFNUSU6JRWK=
NCI-H2126	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwNU[4NVUh\|ryP	M2rqWHNCVkeHUh?=
SNU-C2B	M2jzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XFV2lEPTB;MD61O\|k4PyEQvF2=	MnPsV2FPT0WU
DBTRG-05MG	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwNUiwOVMh\|ryP	NIXPN4ZUSU6JRWK=
MKN1	NWnzSpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnKwTWM2OD1yLkW4O\|g{KM7:TR?=	M{CxRnNCVkeHUh?=
ES3	NIOwU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LUUGlEPTB;MD61PVEzPCEQvF2=	MYDTRW5ITVJ?
OVCAR-3	M1WwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3iTWM2OD1yLkW5N\|QyKM7:TR?=	MmmyV2FPT0WU
ACHN	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HFXWlEPTB;MD62NFU3QSEQvF2=	M1HvUXNCVkeHUh?=
SW872	MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTvOYFWUUN3ME2wMlYxPzZ\|IN88US=>	NUPndFAyW0GQR1XS
CP66-MEL	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnHPW9KSzVyPUCuOlA6PjlizszN	M{PjfHNCVkeHUh?=
NCI-H661	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jnZWlEPTB;MD62NVExPCEQvF2=	M{\GNXNCVkeHUh?=
UACC-893	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzVTWM2OD1yLk[zOlgyKM7:TR?=	MWjTRW5ITVJ?
JVM-3	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3GTWM2OD1yLk[zPFA1KM7:TR?=	MVjTRW5ITVJ?
SF268	NHTGOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXkcmlKSzVyPUCuOlQ{PDlizszN	NV2wcVhDW0GQR1XS
OCI-AML2	M331fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnFdGgxUUN3ME2wMlY2Ozl5IN88US=>	NFzsdmxUSU6JRWK=
RPMI-8226	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17y[2lEPTB;MD62OlMzOyEQvF2=	NVzzcFBtW0GQR1XS
MKN28	M3jlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwNk[2NlQh\|ryP	M37VZ3NCVkeHUh?=
MDA-MB-453	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwNkexPEDPxE1?	NYS4cplPW0GQR1XS
BV-173	NFLjUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj3eIxHUUN3ME2wMlY5Pjd7IN88US=>	NY\lT5ZbW0GQR1XS
NCI-H358	M1zh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjRUY9FUUN3ME2wMlY5PzJ4IN88US=>	NX7ISIdGW0GQR1XS
NCI-H1651	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzzOHpKSzVyPUCuO{DPxE1?	MVfTRW5ITVJ?
MDA-MB-415	NHzv[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwN{C4Nlkh\|ryP	NHT1b4ZUSU6JRWK=
8305C	NV3Qc4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm2fJBKSzVyPUCuO\|I1QThizszN	MoDlV2FPT0WU
EFM-19	NWHabZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\vN3VKSzVyPUCuO\|M3PzFizszN	Mo\vV2FPT0WU
RERF-LC-MS	NHHnNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTXTWM2OD1yLke0OlE{KM7:TR?=	NIDwXIxUSU6JRWK=
A388	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn0cZBlUUN3ME2wMlc3PDZ5IN88US=>	NWe5TY1EW0GQR1XS
GI-ME-N	NY\tUWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTBwN{eyN\|Uh\|ryP	M2j4VHNCVkeHUh?=
IGR-1	NEj3TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nkV2lEPTB;MD63PVA1OyEQvF2=	M4j3UXNCVkeHUh?=
LNCaP-Clone-FGC	M2jMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDxTWM2OD1yLkiwNFA1KM7:TR?=	MWrTRW5ITVJ?
SK-MEL-3	MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3m5WGlEPTB;MD64NVUxQCEQvF2=	M33YenNCVkeHUh?=
UACC-257	NW[wOohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPaTWM2OD1yLkiyNlMyKM7:TR?=	NISwUolUSU6JRWK=
OE33	M4roeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYW4ZYM{UUN3ME2wMlg2OTBzIN88US=>	MY\TRW5ITVJ?
QIMR-WIL	NFGxSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\mcmlEPTB;MD64OVE1OSEQvF2=	NGXmN41USU6JRWK=
NCI-H2009	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13OWGlEPTB;MD64OVMyOSEQvF2=	MYHTRW5ITVJ?
NCI-H522	M1POOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnW1TWM2OD1yLki3O\|g{KM7:TR?=	NYPPSZhTW0GQR1XS
Saos-2	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;RPWlEPTB;MD64O\|g4OSEQvF2=	NFXKZ2NUSU6JRWK=
NB17	NHvRNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknvTWM2OD1yLki4NFI2KM7:TR?=	M37TZXNCVkeHUh?=
D-392MG	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwOEmzOVYh\|ryP	MV;TRW5ITVJ?
SHP-77	NFHRXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEKxVGZKSzVyPUCuPVA1QDVizszN	NYr2WnVJW0GQR1XS
SK-MEL-30	NHLid5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwOUGxPFUh\|ryP	MmXEV2FPT0WU
GCIY	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\LTWM2OD1yLkmxPFQ{KM7:TR?=	NHezcFdUSU6JRWK=
HCC70	NXvtcXpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnrZVY6UUN3ME2wMlkzODV7IN88US=>	MlHhV2FPT0WU
LU-65	M4DKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwOUK1PVEh\|ryP	MXLTRW5ITVJ?
NCI-H1563	NYXYfFRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;GO\|lCUUN3ME2wMlk1QDZ3IN88US=>	MWfTRW5ITVJ?
KURAMOCHI	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwOUWxPVIh\|ryP	MnnYV2FPT0WU
PA-1	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3FPGxKSzVyPUCuPVU1OjRizszN	NUD3bZAzW0GQR1XS
NOS-1	NGDQV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2OydWlEPTB;MD65O\|Q5QSEQvF2=	M1\LfHNCVkeHUh?=
NCI-H69	M1vHWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL3TWM2OD1yLkm3OlM1KM7:TR?=	NEHXbpZUSU6JRWK=
KYSE-450	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnH3TWM2OD1yLkm4OlI3KM7:TR?=	MYDTRW5ITVJ?
8505C	NYjhUGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;Oe4pEUUN3ME2wMlk6QTh{IN88US=>	NV;xV\|UzW0GQR1XS
TGBC24TKB	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoSyTWM2OD1zLkCwNFg1KM7:TR?=	NYO1TXpPW0GQR1XS
PFSK-1	M2f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPkZmpKSzVyPUGuNFE1OjhizszN	MWfTRW5ITVJ?
EKVX	M3TYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnDdYdKSzVyPUGuNFMyOjFizszN	M3;SVnNCVkeHUh?=
RCM-1	NUDPZY52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwMEW1NFch\|ryP	M37CdnNCVkeHUh?=
SW900	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDDd2JKSzVyPUGuNFc5OyEQvF2=	NGjjNIRUSU6JRWK=
D-542MG	M2To[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2SxbmlEPTB;MT6wO\|g2PSEQvF2=	MW\TRW5ITVJ?
SK-PN-DW	M2DYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3FTWM2OD1zLkGwNFU3KM7:TR?=	MWTTRW5ITVJ?
NCI-H727	M{e1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHG3Tm1KSzVyPUGuNVAyPTRizszN	NXjNUYZZW0GQR1XS
SW837	M1fNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfmU3ZKSzVyPUGuNVA6PTRizszN	NHTHSY5USU6JRWK=
BT-20	M1K3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljNTWM2OD1zLkGxNlA1KM7:TR?=	NH7RTHVUSU6JRWK=
RH-18	NVT5VlVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLaTWM2OD1zLkGzNVA{KM7:TR?=	NWDzcpEzW0GQR1XS
TE-12	M1LqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;jbVd2UUN3ME2xMlE{OzN\|IN88US=>	NIXHS4RUSU6JRWK=
NB10	NWjU[o82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYS5fGpjUUN3ME2xMlE{OzR2IN88US=>	Ml3UV2FPT0WU
AU565	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwMUW5O\|Mh\|ryP	NG\EU3JUSU6JRWK=
OAW-42	NV62T41ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFwMUizNFYh\|ryP	NV71O2ZqW0GQR1XS
DJM-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mln0TWM2OD1zLkG5PFgyKM7:TR?=	NE\LS3BUSU6JRWK=
HH	NHjYNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDuTWM2OD1zLkKzPFMyKM7:TR?=	Ml\2V2FPT0WU
LAMA-84	MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDHTWM2OD1zLkK3N\|k1KM7:TR?=	MV\TRW5ITVJ?
KNS-42	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPvOGtKSzVyPUGuN\|AzQTZizszN	M4O4eHNCVkeHUh?=
NCI-H2052	M2jZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3K0TmlEPTB;MT6zNFUxPyEQvF2=	MUTTRW5ITVJ?
MLMA	M2H5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwM{K0NFch\|ryP	NGW2WlVUSU6JRWK=
NB12	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTFwM{W2N\|Yh\|ryP	NWT3[XJkW0GQR1XS
NCI-H1838	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjtdmxkUUN3ME2xMlM3OzB4IN88US=>	M2XPOXNCVkeHUh?=
NCI-H526	M1HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnMcXB[UUN3ME2xMlM4QDV\|IN88US=>	Mo\oV2FPT0WU
LS-123	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr6TWM2OD1zLkO5NFk1KM7:TR?=	NXP3dpFsW0GQR1XS
HDLM-2	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjiTWM2OD1zLkO5NlcyKM7:TR?=	M2G1eHNCVkeHUh?=
MC-IXC	NEDqR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PkZ2lEPTB;MT60NlM4OSEQvF2=	NF3RcodUSU6JRWK=
HCT-15	M2DDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLKTWM2OD1zLkSzNFY5KM7:TR?=	NV\qNZAzW0GQR1XS
NCI-H596	NUX3c3pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXF[GhKSzVyPUGuOFUxPjFizszN	NV7DV\|diW0GQR1XS
ZR-75-30	NILrXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W5WGlEPTB;MT60O\|A5OiEQvF2=	MXTTRW5ITVJ?
A704	NEXHc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFSwWWFKSzVyPUGuOlY2PjNizszN	NGfnUG1USU6JRWK=
OVCAR-4	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C0cmlEPTB;MT62PVYxPyEQvF2=	MUnTRW5ITVJ?
SW1417	NWTKNmhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\rR\|lYUUN3ME2xMlczQDR7IN88US=>	NXzvemFvW0GQR1XS
CAS-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFwN{O5N\|Yh\|ryP	M4rXWHNCVkeHUh?=
IST-SL1	MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlX1TWM2OD1zLke5O\|U6KM7:TR?=	M17S[XNCVkeHUh?=
A253	NHrPTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jKb2lEPTB;MT64NlI{QSEQvF2=	NEC4bVRUSU6JRWK=
EW-16	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[wTWM2OD1zLkiyPFc2KM7:TR?=	M2q1U3NCVkeHUh?=
SK-NEP-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3IflJKSzVyPUGuPFY6QDhizszN	NIrtPVVUSU6JRWK=
NCI-H226	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTFwOEmzOVkh\|ryP	M13JNHNCVkeHUh?=
HOP-92	NIS2SWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDYTWM2OD1zLkm2NFk6KM7:TR?=	M1:0O3NCVkeHUh?=
NCI-H441	NIS4SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjNOJpKSzVyPUKuNFI{OzdizszN	NWHPSJV{W0GQR1XS
LU-139	NGr4[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTpTWM2OD1{LkCzNVE1KM7:TR?=	MknsV2FPT0WU
SJRH30	Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJwMESyOVMh\|ryP	MXXTRW5ITVJ?
MG-63	M1m3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjWTWM2OD1{LkG0NVEyKM7:TR?=	MoPRV2FPT0WU
NH-12	NGroV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4L3TmlEPTB;Mj6xOVAxPiEQvF2=	M3XWfXNCVkeHUh?=
NB7	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVi2[FA4UUN3ME2yMlE6Pjd\|IN88US=>	MYjTRW5ITVJ?
LB771-HNC	NFvrVoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK3OJFKSzVyPUKuNlA2QTVizszN	M3rXcnNCVkeHUh?=
HCC1569	M4C5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnHTWM2OD1{LkK0OVg{KM7:TR?=	MljFV2FPT0WU
D-283MED	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLKdohtUUN3ME2yMlI1Pzh{IN88US=>	M2T6TnNCVkeHUh?=
J-RT3-T3-5	NGfxVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\wPFNKSzVyPUKuNlU{PTFizszN	MWTTRW5ITVJ?
ATN-1	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13rXWlEPTB;Mj6zN\|A5OiEQvF2=	NHHNVo9USU6JRWK=
HCC1954	NIf0dG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTJwM{S0NFgh\|ryP	NYT1RXliW0GQR1XS
SCC-15	M{C3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX2zSWt1UUN3ME2yMlM6OzF{IN88US=>	MonUV2FPT0WU
COLO-668	NW[4WZlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjESIFKSzVyPUKuOFMzKM7:TR?=	NYTWRXRYW0GQR1XS
LB373-MEL-D	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF6zfGxKSzVyPUKuOVQ3PzdizszN	MWnTRW5ITVJ?
no-10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPER21KSzVyPUKuOVQ6PDdizszN	NYnINZROW0GQR1XS
HT-1197	NXXtR3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTJwNkOxPFgh\|ryP	MVvTRW5ITVJ?
DU-145	NXXqbpZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33JO2lEPTB;Mj63PVE3OiEQvF2=	MomxV2FPT0WU
SK-N-AS	M{LLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH31XG1KSzVyPUKuPFQ3QTJizszN	Mnv6V2FPT0WU
MOLT-4	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfuc4NkUUN3ME2yMlg2OzJ{IN88US=>	NFvibG1USU6JRWK=
EW-22	NXLEe41tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTJwOUK4OFEh\|ryP	NIf1SWxUSU6JRWK=
DB	M4j2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTJwOUe3OVkh\|ryP	NETZVpFUSU6JRWK=
HL-60	NGqwNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLsZ\|VDUUN3ME2zMlA1Ozd4IN88US=>	NG[5RohUSU6JRWK=
SK-N-DZ	M2PnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\Wdo5xUUN3ME2zMlA2ODd3IN88US=>	M2jRO3NCVkeHUh?=
NY	M1f3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXSSoVbUUN3ME2zMlA5PTR{IN88US=>	Mki2V2FPT0WU
T47D	NX[zdm9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PDbGlEPTB;Mz6xNFU2QCEQvF2=	NE\MeWhUSU6JRWK=
NCI-H2029	NXjLe41GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnkR5NNUUN3ME2zMlIzPDd5IN88US=>	MknkV2FPT0WU
KARPAS-299	MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTNwMk[wNlch\|ryP	MorVV2FPT0WU
KM-H2	NYHBc2RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3TTWM2OD1\|LkOwOlgh\|ryP	MnT0V2FPT0WU
CHP-134	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTNwNEezPUDPxE1?	Mnj4V2FPT0WU
22RV1	M2P5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T3OmlEPTB;Mz60PVE3QCEQvF2=	NVrDPXVXW0GQR1XS
NB5	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfQOHZKSzVyPUOuOVA3QDlizszN	MnfxV2FPT0WU
CW-2	NXTofFlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrnfGVKSzVyPUOuOVU{OTRizszN	NX\vW2hvW0GQR1XS
EFO-21	MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2frNGlEPTB;Mz61Olk1KM7:TR?=	MlLpV2FPT0WU
HuH-7	NXnoOoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDBTWM2OD1\|LkW4OFE1KM7:TR?=	MkTKV2FPT0WU
ALL-PO	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjITWM2OD1\|Lk[yN\|M2KM7:TR?=	MYDTRW5ITVJ?
EM-2	NXTtdHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XtXWlEPTB;Mz62PVAyOSEQvF2=	Mn\RV2FPT0WU
KLE	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn2TWM2OD1\|LkezNFI6KM7:TR?=	M1TOOnNCVkeHUh?=
NEC8	NVj0ZVFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;kfZhpUUN3ME2zMlkyQDB6IN88US=>	M1niOHNCVkeHUh?=
KP-N-YN	MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37zc2lEPTB;Mz65N\|Q4PiEQvF2=	MYTTRW5ITVJ?
SK-MEL-1	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDZXlJkUUN3ME20MlA{PTF6IN88US=>	M2nH[HNCVkeHUh?=
CAL-54	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHGTWM2OD12LkC1PVEh\|ryP	NFS0[3BUSU6JRWK=
MS-1	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvRdYFIUUN3ME20MlE3OTV3IN88US=>	Mk\BV2FPT0WU
NCI-H209	M4m5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKwb2hKSzVyPUSuNlk6QTlizszN	NWTJPJhFW0GQR1XS
NOMO-1	NHjOT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTRwM{KxN\|Eh\|ryP	M33JTHNCVkeHUh?=
RPMI-2650	M2PPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF6wUVdKSzVyPUSuN\|Y{OjdizszN	M3f1N3NCVkeHUh?=
NCI-H810	NEPYfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrpTWM2OD12LkO5O\|M3KM7:TR?=	MnnBV2FPT0WU
Ca9-22	MnjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrXTYNKSzVyPUSuOFU3QTFizszN	M{nZT3NCVkeHUh?=
ES4	M3PVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE[y[lZKSzVyPUSuOFcxQTVizszN	NFj1fm5USU6JRWK=
ES6	M2TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTRwNEm2OVch\|ryP	MVPTRW5ITVJ?
DMS-114	M{Xwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzmXol5UUN3ME20MlU1PjlzIN88US=>	MkX0V2FPT0WU
ONS-76	NXzFN5FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLCb2ZCUUN3ME20MlU4QTVizszN	M{fFNXNCVkeHUh?=
K-562	NIPEe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrwTWM2OD12LkezPFE1KM7:TR?=	MlvwV2FPT0WU
MHH-NB-11	M2i4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1GxfWlEPTB;ND63OVQ3OSEQvF2=	NV;lcJhLW0GQR1XS
Calu-3	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fKb2lEPTB;ND63PFU1QCEQvF2=	MWDTRW5ITVJ?
HT55	NH;vXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPXTWM2OD12Lki0OVQ2KM7:TR?=	M{DXbXNCVkeHUh?=
SK-N-FI	NI\qUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDUO29KSzVyPUSuPFUxODlizszN	NHjQS4hUSU6JRWK=
ES1	NFLsVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHtcW1HUUN3ME20Mlg3ODV5IN88US=>	NXGwXlkyW0GQR1XS
SF126	NWnOVHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTKTWM2OD12LkmzNVg1KM7:TR?=	MVXTRW5ITVJ?
ES5	NEOwZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3tWmVPUUN3ME21MlEzPDJ5IN88US=>	NFPGOoxUSU6JRWK=
LoVo	M2DTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mny1TWM2OD13LkG1PFcyKM7:TR?=	M{S0VnNCVkeHUh?=
SNU-387	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\TXVI6UUN3ME21MlMzOzN7IN88US=>	NFnKVWZUSU6JRWK=
C8166	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTVwM{[zN\|kh\|ryP	MUjTRW5ITVJ?
LS-1034	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTVwNEKzNFch\|ryP	Mn\nV2FPT0WU
GR-ST	NHnCTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmiwTWM2OD13LkWyNlAyKM7:TR?=	NF7Mc\|RUSU6JRWK=
NCI-H1092	NGXjeW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK2TWM2OD13LkeyPFQ{KM7:TR?=	MmjqV2FPT0WU
647-V	NYHpPWp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{exUmlEPTB;NT63OFcxPiEQvF2=	NE[zcGhUSU6JRWK=
EW-13	Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTVwN{[2Nlch\|ryP	MYrTRW5ITVJ?
KGN	M1rzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\reGlEPTB;Nj6wPVkzOSEQvF2=	M3W5THNCVkeHUh?=
D-423MG	NH24NHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIe1To5KSzVyPU[uOFAzQDRizszN	MkCxV2FPT0WU
ECC10	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzGfGtiUUN3ME23MlExOTBzIN88US=>	M1LyZnNCVkeHUh?=
TE-5	NXXGXGd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf2NWtjUUN3ME23MlQyOjl6IN88US=>	NHmzVpJUSU6JRWK=
P12-ICHIKAWA	M324cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULJZnZ[UUN3ME23MlQ2PTJ\|IN88US=>	MmrDV2FPT0WU
NCI-H82	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFq1VmJKSzVyPUeuOFU4ODFizszN	MmfSV2FPT0WU
NCI-H1993	NH\ZfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;qb4tKSzVyPUeuPFMxPjNizszN	NVjjb4YyW0GQR1XS
RH-1	NWrTe4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTdwOEWyOFQh\|ryP	MYTTRW5ITVJ?
SW948	M32yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLmTWM2OD15Lkm2NFQ6KM7:TR?=	M3fMRXNCVkeHUh?=
CAL-33	NV7BeXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3yxR2lEPTB;Nz65PVk{QCEQvF2=	MYHTRW5ITVJ?
U-266	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvZNXpKSzVyPUiuNVU4PzdizszN	M3;YbHNCVkeHUh?=
CAL-72	M3fmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRThwMkCzNkDPxE1?	MmXpV2FPT0WU
SNU-423	MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTlwM{[2OlYh\|ryP	MljHV2FPT0WU
KG-1	NXfHdJdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXWTWM2OD17LkW4OFU3KM7:TR?=	MX7TRW5ITVJ?
HCC1395	NHjNVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTlwOUKzOVIh\|ryP	MXnTRW5ITVJ?
BE-13	M3fxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvoTWM2OD1zMD64PFkzKM7:TR?=	M32zNHNCVkeHUh?=
MKN7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFyLkm3OlUh\|ryP	NIT5NopUSU6JRWK=
697	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\5V4RXUUN3ME2xNU4yPDd{IN88US=>	MonLV2FPT0WU
LU-135	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvOTWM2OD1zMT6yN\|A4KM7:TR?=	MoTJV2FPT0WU
ES7	NFzEdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Ppb2lEPTB;MUGuN\|MyOyEQvF2=	M1rNT3NCVkeHUh?=
SK-HEP-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfKTWM2OD1zMT63OlQ3KM7:TR?=	MUfTRW5ITVJ?
BEN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFzLki1NUDPxE1?	MljVV2FPT0WU
NCI-H1770	NH7W[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF{LkGyOkDPxE1?	MYHTRW5ITVJ?
SW13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHHZnBKSzVyPUGyMlE2PDFizszN	M4HFNXNCVkeHUh?=
MZ1-PC	M1Xhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[zPW1KSzVyPUGyMlU1PTJizszN	NGXReoNUSU6JRWK=
Mo-T	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlWzTWM2OD1zMj63OFIyKM7:TR?=	MnjsV2FPT0WU
HLE	M1\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHOxT5FKSzVyPUGyMlgzOTVizszN	NXv0PZAxW0GQR1XS
RCC10RGB	NHvjb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnzTWM2OD1zMz62O\|Eh\|ryP	MV7TRW5ITVJ?
COLO-320-HSR	M4fsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnJe5lKSzVyPUGzMlc{QDFizszN	NYi3WlJvW0GQR1XS
BHT-101	NFmz[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPqTWM2OD1zMz64N\|Q2KM7:TR?=	M1XU[3NCVkeHUh?=
OCUB-M	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1iwSmlEPTB;MUSuNVYxOiEQvF2=	MofWV2FPT0WU
MEG-01	M4rXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7zWZVKSzVyPUG0MlM4ODhizszN	M37KOHNCVkeHUh?=
RS4-11	NIi3WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTlTWM2OD1zND63OFIh\|ryP	NEW4cYdUSU6JRWK=
MN-60	NXTZe45rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF2Lke4PVQh\|ryP	NWLvVXNlW0GQR1XS
NCI-H1304	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF3LkC0NlUh\|ryP	M4HETnNCVkeHUh?=
Ramos-2G6-4C10	NV:zfFJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvobZh4UUN3ME2xOU4xPThzIN88US=>	MofxV2FPT0WU
NCI-H2342	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF3LkKwOFQh\|ryP	MUPTRW5ITVJ?
LAN-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLtTWM2OD1zNT60OFE1KM7:TR?=	MVrTRW5ITVJ?
JVM-2	NXjRZpNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDETWM2OD1zNT61O\|Q5KM7:TR?=	MnfCV2FPT0WU
P30-OHK	NWf0eW9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XjUGlEPTB;MU[uNFYyPCEQvF2=	MXHTRW5ITVJ?
C-33-A	NGj4UoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4O1SmlEPTB;MU[uOlIyPCEQvF2=	NEjjdo1USU6JRWK=
RPMI-8866	NXHJPGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTF4Lki0PVYh\|ryP	NIrUNlBUSU6JRWK=
NCI-H630	NHXzRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT4[YpxUUN3ME2xOk45PTN5IN88US=>	NEixeFZUSU6JRWK=
KYSE-140	M1Tsc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3O1TGlEPTB;MUeuNlAzQCEQvF2=	M2\ZUnNCVkeHUh?=
T84	NWrZbVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTTTWM2OD1zOD64Olk2KM7:TR?=	NHnxboxUSU6JRWK=
KU-19-19	M1rCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTPWHBKSzVyPUG4Mlk3ODhizszN	MoXiV2FPT0WU
BALL-1	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTF7LkOzPVkh\|ryP	M4LHRnNCVkeHUh?=
Calu-6	NHjHOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHexT\|lKSzVyPUG5MlQ6OiEQvF2=	M3fFdHNCVkeHUh?=
EGI-1	MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLyTWM2OD1zOT61PVgh\|ryP	M3H0Z3NCVkeHUh?=
MFH-ino	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rEZ2lEPTB;MUmuO\|Q2PCEQvF2=	NGHqRXpUSU6JRWK=
GB-1	NHjrXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{excmlEPTB;MkCuN\|U{PSEQvF2=	NGXUV3RUSU6JRWK=
NCI-H1693	M2L6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPVbW1jUUN3ME2yNE43PTB3IN88US=>	NEjpcGpUSU6JRWK=
SW1116	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfKTWM2OD1{MD65N\|YzKM7:TR?=	NVTKbnVuW0GQR1XS
H-EMC-SS	NWf1WG9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofpTWM2OD1{Mj6wOFUh\|ryP	MlrnV2FPT0WU
D-502MG	NUPiSZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3frUGlEPTB;MkKuPFI3OSEQvF2=	M{TaZXNCVkeHUh?=
IA-LM	M1W4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTJ\|LkK0PVMh\|ryP	NHnVN5FUSU6JRWK=
SW1463	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1eyR2lEPTB;MkOuO\|kh\|ryP	MoTvV2FPT0WU
JAR	NXm5WlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;NNVhQUUN3ME2yOE4{Ojl\|IN88US=>	M{PpcXNCVkeHUh?=
HT	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;wRWlEPTB;MkSuOFc2OyEQvF2=	MV7TRW5ITVJ?
LCLC-103H	NFrOTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nvT2lEPTB;MkSuPFQ1QSEQvF2=	M2SzXHNCVkeHUh?=
SNU-449	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:3TWM2OD1{ND64O\|QyKM7:TR?=	M3T6RnNCVkeHUh?=
KE-37	M33wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nhSmlEPTB;MkWuNFkzQCEQvF2=	M1XQcHNCVkeHUh?=
NCI-H1623	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP6N5VKSzVyPUK3MlE{ODNizszN	NHnhfmtUSU6JRWK=
MOLT-13	NEW5T2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3pTWM2OD1{Nz6zOVE3KM7:TR?=	NUO3bo5ZW0GQR1XS
COLO-741	M2rjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NICwZmhKSzVyPUOxMlM{OzNizszN	M{XNZXNCVkeHUh?=
NB6	NXPXd2JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTN{LkK4O\|Yh\|ryP	NWP4TpRTW0GQR1XS
MOLT-16	M4rpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnj[XBKSzVyPUOzMlAxPTVizszN	M1G4RnNCVkeHUh?=
IST-MES1	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXS3bZdYUUN3ME2zOE4xPTRzIN88US=>	NVnFTVdbW0GQR1XS
A4-Fuk	M{f4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED1[ZVKSzVyPUO1MlA3PiEQvF2=	M{i1WnNCVkeHUh?=
CAL-85-1	M1nF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofXTWM2OD1\|NT6yPFE4KM7:TR?=	NUHzO\|BDW0GQR1XS
CCRF-CEM	M2HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTN5LkG1N\|Yh\|ryP	MVXTRW5ITVJ?
HAL-01	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq2bYxKSzVyPUO4MlQ5QDlizszN	MleyV2FPT0WU
HEL	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTR\|LkO0NFkh\|ryP	MW\TRW5ITVJ?
EW-1	NELPWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\zUWlEPTB;NEOuOFc3QCEQvF2=	NYDCXYxoW0GQR1XS
MDA-MB-231	M{Tocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL1TWM2OD12NT6xNVk6KM7:TR?=	MVfTRW5ITVJ?
ABC-1	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTR4Lki1N\|gh\|ryP	MmfWV2FPT0WU
NCI-H446	NHi5c2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHLTWM2OD12OD61NFU5KM7:TR?=	NX\UTm53W0GQR1XS
MHH-PREB-1	NYnjeHd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTR7Lk[wNFch\|ryP	MlrlV2FPT0WU
DOHH-2	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfrV4o{UUN3ME20PU43PjV4IN88US=>	MVLTRW5ITVJ?
GCT	NU\TTnMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T3OGlEPTB;NEmuOlk4PiEQvF2=	MX\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00577889	Completed	Adenocarcinoma of the Pancreas\|Recurrent Pancreatic Cancer\|Stage IV Pancreatic Cancer	National Cancer Institute (NCI)	March 2008	Phase 2
NCT00546780	Completed	Multiple Myeloma	Bristol-Myers Squibb	February 2008	Phase 3
NCT00093496	Completed	Primary Peritoneal Cavity Cancer\|Recurrent Ovarian Epithelial Cancer\|Stage III Ovarian Epithelial Cancer\|Stage IV Ovarian Epithelial Cancer	National Cancer Institute (NCI)	October 2007	Phase 2
NCT00514371	Completed	Multiple Myeloma	Bristol-Myers Squibb	August 2007	Phase 2\|Phase 3
NCT00779428	Completed	Advanced Malignancies	Bristol-Myers Squibb	July 2006	Phase 2
NCT00354185	Terminated	Adult Nasal Type Extranodal NK/T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Stage III Adult Burkitt Lymphoma\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Mixed Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Adult Hodgkin Lymphoma\|Stage III Adult Immunoblastic Large Cell Lymphoma\|Stage III Adult Lymphoblastic Lymphoma\|Stage III Adult T-cell Leukemia/Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Grade 3 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides/Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Burkitt Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Mixed Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Adult Hodgkin Lymphoma\|Stage IV Adult Immunoblastic Large Cell Lymphoma\|Stage IV Adult Lymphoblastic Lymphoma\|Stage IV Adult T-cell Leukemia/Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Grade 3 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides/Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|Unspecified Adult Solid Tumor Protocol Specific\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	May 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products4

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 20 Publications

9 Customer Reviews

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-11-16)

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)